Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Oct 15;94(8):1047-50.
doi: 10.1016/j.amjcard.2004.06.065.

Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent

Seung-Woon Rha  1 , Pramod K Kuchulakanti, Rajbabu Pakala, Edouard Cheneau, Jana A Fournadjiev, Ellen Pinnow, Afework Gebreeyesus, George Aggrey, Zuyue Wang, Augusto D Pichard, Lowell F Satler, Kenneth M Kent, Joseph Lindsay, Ron Waksman
Affiliations
Comparative Study

Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent

Seung-Woon Rha et al. Am J Cardiol. .

Abstract

Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.

PubMed Disclaimer

Publication types

LinkOut - more resources